ClinicalTrials.gg
CompletedNCT00862992Updated Jan 5, 2026Results posted

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

A Phase 2 interventional study of Cariprazine 3 mg and Cariprazine 6 mg in Schizophrenia, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Tanabe Pharma Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
19th of 23
34 · median 129
Started
2008
with 1 other
Phase 2
4 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
6 of 23
Tanabe Pharma Corporation

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 19th largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 2, and was the 4th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia. MP-214 tablets will be administered to patients starting at an initial dose, followed by up-titration to a fixed dose (low, medium or high) for 14 days.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • antipsychotics
  • dopamine D3/D2 antagonist
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients meeting criteria for schizophrenia
  • PANSS total score \<= 120 during the observation period
  • Patients who have been treated with oral antipsychotics within 4 weeks before
  • Patients whose consent is obtained from themselves in written form

Exclusion criteria

Exclusion Criteria:

  • Patients who have defined as any mental disorder other than "Schizophrenia" based on the criteria of
  • History of drug or alcohol abuse
  • Concurrent Parkinson's disease
  • History of, or concurrent spastic disorders like epilepsy, cerebrovascular disease, anuresis or adynamic(= paralytic) ileus, malignant syndrome, diabetes, hepatic disorder
  • Patients who exhibit abnormalities on Physical Examination, have abnormal vital signs, , or clinical laboratory values
  • Current cataract during the observation period
  • History of shock or anaphylactoid symptoms to drugs

The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    1

    Drug: Cariprazine 3 mg

  • Experimental
    2

    Drug: Cariprazine 6 mg

  • Experimental
    3

    Drug: Cariprazine 12.5 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Event and Adverse Drug Reaction

    Time frame: Up to 7 weeks

Secondary outcomes

  1. Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14

    Time frame: Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.

  2. Time to Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14

    Time frame: Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Last of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14

    Time frame: Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.

Other outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 14 (Last Observation Carried Forward; LOCF)

    PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.

    Time frame: at baseline, and on Day 14 or a last observation carried forward (LOCF)

  2. Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Day 14 (Last Observation Carried Forward; LOCF)

    CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).

    Time frame: at baseline, and on Day 14 or a last observation carried forward (LOCF)

  3. The Clinical Global Impression-Improvement (CGI-I) Score at Day 14 (Last Observation Carried Forward; LOCF)

    CGI-I is a 7-point scale to assess the global improvement of the participant's illness relative to baseline. CGI-I scores range from 1 (very much improved) to 7 (very much worse).

    Time frame: on Day 14 or a last observation carried forward (LOCF)

07

Results

Posted Apr 12, 2021

Participant flow

Participant flow — Overall Study
MilestoneCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Started121012
Completed999
Not completed313
Withdrew: Adverse event211
Withdrew: Physician decision100
Withdrew: Withdrawal by subject002

Outcome measures

PrimaryNumber of Participants With Adverse Event and Adverse Drug Reaction
Time frame:
Up to 7 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event and Adverse Drug Reaction
ParticipantsCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Number of Participants With Adverse event9911
Number of Participants With Adverse drug Reaction5610
SecondaryMaximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
Time frame:
Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.
Reported as:
Mean · ng/mL
Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
ng/mLCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Unchanged MP-2149.19 ± 3.4719.43 ± 4.8036.39 ± 8.53
M7 (desmethyl cariprazine)3.14 ± 1.265.83 ± 1.8711.37 ± 3.00
M6 (didesmethyl cariprazine)13.79 ± 5.7428.08 ± 14.5254.99 ± 14.97
SecondaryTime to Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
Time frame:
Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.
Reported as:
Mean · hour
Time to Maximum Plasma Concentration of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
hourCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Unchanged MP-2143.71 ± 0.993.48 ± 1.113.22 ± 0.45
M7 (desmethyl cariprazine)5.25 ± 1.995.10 ± 1.944.36 ± 1.80
M6 (didesmethyl cariprazine)4.79 ± 2.235.37 ± 2.145.22 ± 2.08
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
Time frame:
Pre-dose, 3, 4, 6, 8, 24, 48, 72, 96 and 168 hours post-dose of Day 14.
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Last of Unchanged MP-214, M7 (Desmethyl Cariprazine) and M6 (Didesmethyl Cariprazine) at Day 14
ng*hr/mLCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Unchanged MP-214298.36 ± 128.04522.38 ± 194.611017.96 ± 419.24
M7 (desmethyl cariprazine)135.25 ± 64.80232.38 ± 113.31437.64 ± 131.76
M6 (didesmethyl cariprazine)1884.24 ± 785.733397.12 ± 2395.445950.73 ± 1928.05
Other pre-specifiedChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 14 (Last Observation Carried Forward; LOCF)

PANSS score is a 30-item rating scale to assess both the positive and negative symptom syndromes of patients with schizophrenia. Each item is scored on a 7-point scale, from 1 (absent) to 7 (extreme). The PANSS total score of the 30 PANSS items ranges from 30 to 210. High scores indicate greater severity of symptoms.

Time frame:
at baseline, and on Day 14 or a last observation carried forward (LOCF)
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 14 (Last Observation Carried Forward; LOCF)
units on a scaleCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 14 (Last Observation Carried Forward; LOCF)-0.2 ± 12.8-0.6 ± 15.6-3.9 ± 10.8
Other pre-specifiedChange From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Day 14 (Last Observation Carried Forward; LOCF)

CGI-S is a 7-point scale to assess the global severity of the participant's illness. CGI-S scores range from 1 (normal, not ill at all) to 7 (extremely ill).

Time frame:
at baseline, and on Day 14 or a last observation carried forward (LOCF)
Reported as:
Mean · units on a scale
Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Day 14 (Last Observation Carried Forward; LOCF)
units on a scaleCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score at Day 14 (Last Observation Carried Forward; LOCF)0.3 ± 0.8-0.1 ± 0.9-0.1 ± 0.7
Other pre-specifiedThe Clinical Global Impression-Improvement (CGI-I) Score at Day 14 (Last Observation Carried Forward; LOCF)

CGI-I is a 7-point scale to assess the global improvement of the participant's illness relative to baseline. CGI-I scores range from 1 (very much improved) to 7 (very much worse).

Time frame:
on Day 14 or a last observation carried forward (LOCF)
Reported as:
Mean · units on a scale
The Clinical Global Impression-Improvement (CGI-I) Score at Day 14 (Last Observation Carried Forward; LOCF)
units on a scaleCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
The Clinical Global Impression-Improvement (CGI-I) Score at Day 14 (Last Observation Carried Forward; LOCF)4.1 ± 1.33.7 ± 1.23.8 ± 1.1

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine 3 mg—3/12 (25%)9/12 (75%)
Cariprazine 6 mg—1/10 (10%)9/10 (90%)
Cariprazine 12.5 mg—2/12 (16.7%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
SchizophreniaPsychiatric disorders2/121/101/12
Blood creatine phosphokinase increasedInvestigations0/121/100/12
Tibia fractureInjury, poisoning and procedural complications1/120/100/12
Neuroleptic malignant syndromeNervous system disorders0/120/101/12
Most frequent other events
Showing 10 of 70
Most frequent other events
EventCariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mg
InsomniaPsychiatric disorders4/123/101/12
NasopharyngitisInfections and infestations2/123/101/12
DiarrhoeaGastrointestinal disorders2/121/103/12
Alanine aminotransferase increasedInvestigations1/120/103/12
Blood creatine phosphokinase increasedInvestigations1/121/103/12
White blood cell count increasedInvestigations0/120/103/12
AkathisiaNervous system disorders1/121/103/12
ToothacheGastrointestinal disorders0/122/100/12
NauseaGastrointestinal disorders2/121/100/12
PyrexiaGeneral disorders0/120/102/12

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mgTotal
<18 years0000
>=18 and =<30 years2226
>=31 and =<40 years2439
>=41 and =<55 years63514
>55 years2125
Sex: Female, Male
Sex: Female, Male(Participants)Cariprazine 3 mgCariprazine 6 mgCariprazine 12.5 mgTotal
Female64414
Male66820
08

Study locations

1 site
  • Hoyu Hospital
    Kure, Hiroshima, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2021, 11 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2009
First posted
Mar 17, 2009
Start
Apr 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Apr 12, 2021
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00862992
Responsible party
Sponsor
First posted
Mar 17, 2009
Start date
Apr 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Apr 12, 2021
Last update
Jan 5, 2026

Study contacts

Teruhiko Higuchi, President
study chair · National Center of Neurology and Psychiatry

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion